RNS Number : 7148D
Renalytix PLC
16 October 2025
Renalytix plc
("Renalytix" or the "Company")
Holding(s) in Company
LONDON and NEW YORK, 16 October 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), announces that it has received a TR-1 notification from Harwood Capital LLP following the recent admission of ordinary shares and increase in the Company's total issued share capital (RNS 8264C: $4m balance sheet improvement with bond conversion). The resulting crossing of a threshold is due to an increase in the Company's total issued share capital, rather than any disposal or acquisition of shares. The TR-1 notification is reproduced below.
1. Issuer Details
ISIN
GB00BYWL4Y04
Issuer Name
RENALYTIX PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An event changing the breakdown of voting rights
3. Details of person subject to the notification obligation
Name
Harwood Capital LLP
City of registered office (if applicable)
Country of registered office (if applicable)
Name
City of registered office
Country of registered office
Harwood Capital Management (Gibraltar) Limited
Gibraltar
Gibraltar
Harwood Capital LLP
London
United Kingdom
4. Details of the shareholder
Name
City of registered office
Country of registered office
North Atlantic Smaller Companies Investment Trust Plc
London
United Kingdom
Oryx International Growth Fund Limited
Guernsey
Guernsey
Harwood Capital LLP
London
United Kingdom
5. Date on which the threshold was crossed or reached
15-Oct-2025
6. Date on which Issuer notified
15-Oct-2025
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached
3.903000
0.000000
3.903000
17061345
Position of previous notification (if applicable)
4.411130
0.000000
4.411130
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible)
Number of direct voting rights (DTR5.1)
Number of indirect voting rights (DTR5.2.1)
% of direct voting rights (DTR5.1)
% of indirect voting rights (DTR5.2.1)
GB00BYWL4Y04
11500000
2.631000
GB00BYWL4Y04
4800000
1.098000
GB00BYWL4Y04
761345
0.174000
Sub Total 8.A
17061345
3.903000%
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument
Expiration date
Exercise/conversion period
Number of voting rights that may be acquired if the instrument is exercised/converted
% of voting rights
Sub Total 8.B1
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument
Expiration date
Exercise/conversion period
Physical or cash settlement
Number of voting rights
% of voting rights
Sub Total 8.B2
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person
Name of controlled undertaking
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Christopher Harwood Bernard Mills
North Atlantic Smaller Companies Investment Trust Plc
2.631000
2.631000%
Christopher Harwood Bernard Mills
Oryx International Growth Fund Limited
1.098000
1.098000%
Christopher Harwood Bernard Mills
Harwood Capital LLP
0.174000
0.174000%
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
15/10/2025
13. Place Of Completion
London Stock Exchange
For further information, please contact:
Renalytix plc
www.renalytix.com
James McCullough, CEO
Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)
Tel:+44 (0)20 3470 0470
Jeff Keating / David Hignell(Corporate Finance) Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker)
Tel: +44 (0)20 3179 5300
Mike Seabrook / Nick Lovering
Walbrook PR Limited
Tel: 020 7933 8780 orrenalytix@walbrookpr.com
Paul McManus / Alice Woodings
Mob: 07980 541 893 / 07407 804 654
About Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX.dkd test, visit kidneyintelx.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLFLFFVIDLRLIE
